What does PHARMALIS do?

PHARMALIS is a pharmacy in Neufchâteau. Private Limited, started on 3 January 2003, 1 establishment.

What is the address of PHARMALIS?

The registered office of PHARMALIS is located at Avenue de la Victoire,NEU 54, 6840 Neufchâteau.

Is PHARMALIS still active?

Yes. According to the CBE (30 October 2026) PHARMALIS is active, legal situation “Normale toestand”, started on 3 January 2003.

Is PHARMALIS registered on Peppol?

Yes, PHARMALIS is registered on the Peppol network with ID 0208:0479216325.

What is the enterprise number of PHARMALIS?

The enterprise number of PHARMALIS is BE0479216325.

When was PHARMALIS founded?

PHARMALIS was founded on 3 January 2003.

Who are the directors of PHARMALIS?

According to the 2025 annual accounts, the directors of PHARMALIS are: Vincent LALOUX, Stéphanie NOEL.

Is PHARMALIS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 3 January 2003; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARMALIS make in 2025?

PHARMALIS posted a profit after taxes of € 18,272 in financial year 2025.

What is the revenue of PHARMALIS?

As a small company, PHARMALIS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 336,675.

How much does an employee at PHARMALIS earn?

The average wage cost per full-time employee at PHARMALIS was € 60,300 in 2025: staff costs of € 114,523 for 1.9 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMALIS have?

According to the 2025 annual accounts, PHARMALIS has 1.9 full-time equivalents (FTE).

PHARMALIS (Private Limited) - Neufchâteau - BE0479216325

Dossier PHARMALIS, printed on 30 October 2026 from databakkes.be/en/0479216325/pharmalis. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMALIS from Neufchâteau, company number BE0479216325, closed financial year 2025 with a result of € 18,272 after tax. For that financial year PHARMALIS recorded a gross margin of € 336,675 and equity of € 85,307. Compared with financial year 2024, the result moved from € -61,315 to € 18,272. Profitable, and profit is growing. The buffer shrank hard: equity is 80 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on April 22, 2026.

What it is worth Shrank hard

€ 85,307

▼ 80% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 18,272

▲ still € 61,315 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 566,390

▲ 48% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 370,055 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

1.9

▼ 0.2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 114,523

▼ 29% vs 2024

€ 60,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 7,639

▼ 67% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 123,358

▼ 18% vs 2024

€ 37,609 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 52,875

▲ 18% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 34,831

▲ 43% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 350,757 Gross margin 2022: € 350,757 First fiscal year in the series	€ 364,105 Gross margin 2023: € 364,105 ▲ 4% vs 2022 (€ 350,757) Favourable step	€ 382,642 Gross margin 2024: € 382,642 ▲ 5% vs 2023 (€ 364,105) Favourable step	€ 336,675 Gross margin 2025: € 336,675 ▼ 12% vs 2024 (€ 382,642) Unfavourable step	▼ 12%
Profit after taxes	€ -25,057 Profit after taxes 2022: € -25,057 First fiscal year in the series	€ -49,265 Profit after taxes 2023: € -49,265 ▼ € 24,208 vs 2022 (€ -25,057) Unfavourable step	€ -61,315 Profit after taxes 2024: € -61,315 ▼ € 12,050 vs 2023 (€ -49,265) Unfavourable step	€ 18,272 Profit after taxes 2025: € 18,272 ▲ € 79,587 vs 2024 (€ -61,315) Favourable step	▲ € 79,587
Equity	€ 547,669 Equity 2022: € 547,669 First fiscal year in the series	€ 498,405 Equity 2023: € 498,405 ▼ 9% vs 2022 (€ 547,669) Unfavourable step	€ 437,090 Equity 2024: € 437,090 ▼ 12% vs 2023 (€ 498,405) Unfavourable step	€ 85,307 Equity 2025: € 85,307 ▼ 80% vs 2024 (€ 437,090) Unfavourable step	▼ 80%
Total debts	€ 864,573 Total debts 2022: € 864,573 First fiscal year in the series	€ 741,955 Total debts 2023: € 741,955 ▼ 14% vs 2022 (€ 864,573) Favourable step	€ 716,217 Total debts 2024: € 716,217 ▼ 3% vs 2023 (€ 741,955) Favourable step	€ 1,011,157 Total debts 2025: € 1,011,157 ▲ 41% vs 2024 (€ 716,217) Unfavourable step	▲ 41%
Cash	€ 448,283 Cash 2022: € 448,283 First fiscal year in the series	€ 176,230 Cash 2023: € 176,230 ▼ 61% vs 2022 (€ 448,283) Unfavourable step	€ 383,907 Cash 2024: € 383,907 ▲ 118% vs 2023 (€ 176,230) Favourable step	€ 566,390 Cash 2025: € 566,390 ▲ 48% vs 2024 (€ 383,907) Favourable step	▲ 48%
Land & buildings	€ 262,484 Land & buildings 2022: € 262,484 First fiscal year in the series	€ 247,818 Land & buildings 2023: € 247,818 ▼ 6% vs 2022 (€ 262,484) Unchanged	€ 255,895 Land & buildings 2024: € 255,895 ▲ 3% vs 2023 (€ 247,818) Unchanged	€ 246,354 Land & buildings 2025: € 246,354 ▼ 4% vs 2024 (€ 255,895) Unchanged	▼ 4%
Retained profit	€ 520,622 Retained profit 2022: € 520,622 First fiscal year in the series	€ 471,358 Retained profit 2023: € 471,358 ▼ 9% vs 2022 (€ 520,622) Unfavourable step	€ 410,043 Retained profit 2024: € 410,043 ▼ 13% vs 2023 (€ 471,358) Unfavourable step	€ 58,260 Retained profit 2025: € 58,260 ▼ 86% vs 2024 (€ 410,043) Unfavourable step	▼ 86%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 370,055 Dividend 2025: € 370,055 Unchanged (€ 0) Unchanged
Bank debt	€ 195,543 Bank debt 2022: € 195,543 First fiscal year in the series	€ 164,352 Bank debt 2023: € 164,352 ▼ 16% vs 2022 (€ 195,543) Favourable step	€ 150,456 Bank debt 2024: € 150,456 ▼ 8% vs 2023 (€ 164,352) Favourable step	€ 123,358 Bank debt 2025: € 123,358 ▼ 18% vs 2024 (€ 150,456) Favourable step	▼ 18%
Balance sheet total	€ 1,412,242 Balance sheet total 2022: € 1,412,242 First fiscal year in the series	€ 1,240,360 Balance sheet total 2023: € 1,240,360 ▼ 12% vs 2022 (€ 1,412,242) Unchanged	€ 1,153,307 Balance sheet total 2024: € 1,153,307 ▼ 7% vs 2023 (€ 1,240,360) Unchanged	€ 1,096,463 Balance sheet total 2025: € 1,096,463 ▼ 5% vs 2024 (€ 1,153,307) Unchanged	▼ 5%
Employees (FTE)	-	-	2.1 Employees (FTE) 2024: 2.1 First fiscal year in the series	1.9 Employees (FTE) 2025: 1.9 ▼ 0.2 vs 2024 (2.1) Unchanged	▼ 0.2

Key figures of PHARMALIS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMALIS?

What happened at PHARMALIS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 22, 2026 New annual accounts for financial year 2025: profit of € 18,272. Source: NBB ↗
2021 Vincent LALOUX became a director. NBB
2021 Stéphanie NOEL became a director. NBB
Apr 1, 2003 New establishment in Neufchâteau. KBO
Jan 3, 2003 Start of the company according to the CBE. KBO

In short

From € 25,057 loss in 2022 to € 18,272 profit in 2025.

Paid € 169,817 in corporate taxes since 2022.

Best year ever: 2025, with € 18,272 profit.

On average € 177,200 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Vincent LALOUX Stéphanie NOEL

PHARMALIS

Behind PHARMALIS are Vincent LALOUX and Stéphanie NOEL.

Directors

According to the 2025 annual accounts

Vincent LALOUX

Director

since 2021

Stéphanie NOEL

Director

since 2021

Establishments

Establishment units

Physical locations of this company

Registered office

Avenue de la Victoire,NEU 54

6840 Neufchâteau

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0479.216.325

VAT number

BE 0479.216.325

Registered office

Avenue de la Victoire,NEU 54, 6840 Neufchâteau

Names & denominations

PHARMALIS

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

3 January 2003

Peppol

Active · Active since 14 Feb 2025

Contact

[email protected] 061/27.15.20

Activities · NACE

Detailhandel in farmaceutische producten

Overige zakelijke dienstverlening, neg

Overige zakelijke dienstverlening, n.e.g.

Activiteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMALIS

Financials

What happened to PHARMALIS?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions